Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
Open Access
- 6 July 2018
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 144 (2), 389-401
- https://doi.org/10.1002/ijc.31662
Abstract
PIK3CA is a frequently mutated gene in cancer, including about ∼15 to 20% of colorectal cancers (CRC). PIK3CA mutations lead to activation of the PI3K/AKT/mTOR signaling pathway, which plays pivotal roles in tumorigenesis. Here, we investigated the mechanism of resistance of PIK3CA‐mutant CRC cell lines to gedatolisib, a dual PI3K/mTOR inhibitor. Out of a panel of 29 CRC cell lines, we identified 7 harboring one or more PIK3CA mutations; of these, 5 and 2 were found to be sensitive and resistant to gedatolisib, respectively. Both of the gedatolisib‐resistant cell lines expressed high levels of active glycogen synthase kinase 3‐beta (GSK3β) and harbored the same frameshift mutation (c.465_466insC; H155fs*) in TCF7, which encodes a positive transcriptional regulator of the WNT/β‐catenin signaling pathway. Inhibition of GSK3β activity in gedatolisib‐resistant cells by siRNA‐mediated knockdown or treatment with a GSK3β‐specific inhibitor effectively reduced the activity of molecules downstream of mTOR and also decreased signaling through the WNT/β‐catenin pathway. Notably, GSK3β inhibition rendered the resistant cell lines sensitive to gedatolisib cytotoxicity, both in vitro and in a mouse xenograft model. Taken together, these data demonstrate that aberrant regulation of WNT/β‐catenin signaling and active GSK3β induced by the TCF7 frameshift mutation cause resistance to the dual PI3K/mTOR inhibitor gedatolisib. Co‐treatment with GSK3β inhibitors may be a strategy to overcome the resistance of PIK3CA‐ and TCF7‐mutant CRC to PI3K/mTOR‐targeted therapies.Funding Information
- Ministry of Education of the Republic of Korea (2009‐0093820)
- National Research Foundation of Korea (2017M3C9A5029978)
This publication has 51 references indexed in Scilit:
- Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferationProceedings of the National Academy of Sciences of the United States of America, 2011
- Inhibition of GSK3 by Wnt signalling – two contrasting modelsJournal of Cell Science, 2011
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axisProceedings of the National Academy of Sciences of the United States of America, 2011
- Glycogen synthase kinase 3β inhibitors protect hippocampal neurons from radiation-induced apoptosis by regulating MDM2-p53 pathwayCell Death & Differentiation, 2011
- A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial CarcinomasClinical Cancer Research, 2011
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of AktMolecular Cell, 2006
- Wnt Activation and Alternative Promoter Repression of LEF1 in Colon CancerMolecular and Cellular Biology, 2006
- Deregulated GSK3β activity in colorectal cancer: Its association with tumor cell survival and proliferationBiochemical and Biophysical Research Communications, 2005